8-K: Aditxt to Acquire Appili Therapeutics in $20 Million Deal, Bolstering Infectious Disease Portfolio

Aditxt has signed a definitive agreement to acquire Appili Therapeutics, a biopharmaceutical company with a focus on infectious diseases and medical countermeasures, for approximately $20 million.

Summary

• Aditxt, Inc. has agreed to acquire Appili Therapeutics Inc. through a court-approved plan of arrangement.
• The acquisition includes Appili's FDA-approved LIKMEZ, a taste-masked oral suspension for bacterial infections, and two vaccine programs, ATI-1701 for tularemia and ATI-1801 for cutaneous leishmaniasis.
• Appili has secured a $14 million non-dilutive award from the U.S. Department of Defense for the development of ATI-1701.
• The transaction involves Aditxt acquiring all outstanding Appili shares, with Appili shareholders receiving a combination of Aditxt stock and cash.
• Appili shareholders will receive 0.002745004 of an Aditxt share and $0.0467 in cash for each Appili share, totaling approximately $0.0561 per share based on Aditxt's stock price on March 28, 2024.
• Appili shareholders will own approximately 19.99% of Aditxt after the transaction.
• Aditxt will repay at least 50% of Appili's senior secured debt at closing and the remainder by December 31, 2024.
• The deal is contingent on Aditxt raising at least $20 million in financing and is expected to close in early Q3 2024.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the acquisition, highlighting the strategic benefits and potential synergies. However, it also acknowledges the risks and conditions associated with the deal, resulting in a moderately positive sentiment.

Positives

• The acquisition enhances Aditxt's portfolio with FDA-approved LIKMEZ and promising vaccine programs.
• Appili's biodefense program, ATI-1701, has secured significant non-dilutive funding from the U.S. DoD.
• The acquisition creates synergies with Aditxt's existing programs, particularly in precision diagnostics.
• Appili can leverage Aditxt's research and development, operations, and commercialization expertise.
• Aditxt, as a NASDAQ-listed company, can facilitate capital access for Appili.

Negatives

• The transaction is contingent on Aditxt raising at least $20 million in financing.
• Appili's shareholders will experience dilution, owning approximately 19.99% of Aditxt after the transaction.
• Aditxt will assume Appili's outstanding liabilities and indebtedness.
• The transaction is subject to customary conditions, including regulatory and stock exchange approvals.

Risks

• The acquisition may not be completed if Aditxt fails to raise the required $20 million in financing.
• The transaction is subject to regulatory and shareholder approvals, which may not be obtained.
• There is a risk of not realizing the anticipated benefits and synergies from the acquisition.
• Appili's programs may not be eligible for Priority Review Vouchers, impacting potential revenue.
• The market price of Aditxt's stock could be adversely affected by the transaction.

Future Outlook

The document includes forward-looking statements regarding the ability to close the transaction, secure regulatory approvals, and realize the anticipated benefits. It also mentions the potential for Appili to secure Priority Review Vouchers and for Aditxt to leverage Appili for future acquisitions and licensing agreements.

Management Comments

• Amro Albanna, CEO of Aditxt, stated that the acquisition of Appili would represent another step in Aditxt's journey towards advancing promising innovations in health.
• Dr. Don Cilla, CEO of Appili Therapeutics, said that the transaction aligns with their goals on multiple levels and that Aditxt can facilitate capital access in this challenging economic environment.

Industry Context

This acquisition reflects a trend in the pharmaceutical industry where companies are consolidating to expand their pipelines and capabilities, particularly in high-growth areas like infectious diseases and biodefense. The deal also highlights the importance of government funding in advancing medical countermeasures.

Comparison to Industry Standards

• The acquisition of Appili by Aditxt is similar to other acquisitions in the biotech space where larger companies acquire smaller firms with promising drug candidates or technologies.
• The $14 million non-dilutive funding from the U.S. DoD for ATI-1701 is a significant amount, comparable to other government grants for biodefense programs.
• The potential for Priority Review Vouchers (PRVs) is a common incentive in the pharmaceutical industry, with recent secondary market transactions ranging from $80 million to $100 million, similar to other PRV valuations.
• The structure of the deal, involving a combination of stock and cash, is a typical approach in biotech acquisitions, balancing immediate value for shareholders with potential future upside.
• The 19.99% ownership stake for Appili shareholders in Aditxt is a common outcome in acquisitions, reflecting the value of the acquired company and the dilution of the acquiring company's existing shareholders.

Stakeholder Impact

• Appili shareholders will receive a combination of Aditxt stock and cash.
• Aditxt shareholders will experience dilution but gain access to Appili's assets and pipeline.
• Employees of both companies may experience changes due to the integration.
• Customers and partners of both companies may see changes in product offerings and collaborations.

Next Steps

• Aditxt needs to secure at least $20 million in financing.
• Appili shareholders will vote on the transaction at a special meeting.
• The companies will seek necessary court, regulatory, and stock exchange approvals.
• The transaction is expected to close in early Q3 2024.

Key Dates

Keywords

acquisition, biopharmaceutical, infectious diseases, vaccine, FDA approval, biodefense, medical countermeasures, priority review voucher, financing, merger